AriBio's Phase 3 readout decides whether Fosun pays another $80 million for AR1001

Fosun Pharma already held AR1001's rights for Greater China, and Samjin Pharmaceutical holds Korean manufacturing and exclusive sales rights ^[5]. The May option was therefore a purchase of the rest of the world, North America included ^[6]. Add the $80 million exercise payment ^[7] to the $60 million fee and the disclosed price of global rights comes to $140 million ^[1]. About 43% of that is already in AriBio's hands, and the other 57% depends on one readout ^[2]. The report does not include milestone or royalty terms, so $140 million is only the published part of the price ^[1].

That structure limits Fosun's loss to the fee it has spent ^[6]. Until the topline arrives, Fosun has put no money into North America beyond the option, because its decision on a definitive agreement comes after it reviews the results ^[2]. AriBio carries the other side of the bet, on a compound built from mirodenafil, an SK Chemicals erectile dysfunction ingredient it licensed in 2011 and has been developing for Alzheimer's ^[4].

The timing is shared as well. "Since Fosun Pharma will decide whether to proceed with a definitive agreement after reviewing the topline results, we will disclose the data as soon as both companies have confirmed it," an AriBio official told Seoul Economic Daily ^[2]. The release date depends partly on the counterparty's review, and the detailed data wait for an oral presentation at the CTAD conference in November ^[3].

If the topline is clean and Fosun exercises, AriBio collects $80 million and a global partner ^[7]. Clean data followed by a slow or declined exercise would leave AriBio with good results and, presumably, North American rights still unsold, and the market would have to price that gap. A mixed result is where the joint sign-off matters most, since the data go out only once both companies have confirmed them ^[2].

The rest of the October list is softer. SK Biopharmaceuticals' epilepsy candidate opacalim is under a partial FDA clinical hold over toxicity seen in animal toxicology studies ^[8], and Biohaven, the original developer, has yet to send the additional non-clinical data it plans to submit ^[9]. "We expect the clinical hold could be lifted as early as this month," an SK Biopharmaceuticals official said ^[10]. An October lift needs Biohaven's filing and the FDA's answer inside the same few weeks ^[9].

Hanmi Pharmaceutical's Efpe is closer to a scheduled event. The company expects the Ministry of Food and Drug Safety to approve the obesity drug in October ^[12]. Hanmi is reportedly preparing to price it below Wegovy and Mounjaro ^[13].

Two companies have already loosened their own dates. Yuhan's R&D head Kim Yeol-hong said early this year that the company "will be able to deliver good news in the third quarter," and at a May R&D Day he stressed that a licensing deal was imminent ^[15]. That quarter ended on Sept. 30 with the report still describing Yuhan's pipeline news as coming soon ^[4]. A Yuhan official added that "since this is a contract involving a counterparty, the timing could change" ^[16]. Peptron's technology evaluation agreement with Eli Lilly, signed on Oct. 7, 2024 ^[17], reaches its two-year mark on Oct. 7 ^[3], and Peptron said in a notice that "the joint research period and the timing of a definitive agreement are separate matters" ^[18].

I think October is a yes-or-no test for AriBio and a set of movable dates for most of the others. The opposing view comes from the report itself: "Corporate valuations are expected to diverge depending on clinical results, technology licensing deals and regulatory decisions," an industry official said ^[21]. If Yuhan and Peptron both sign definitive deals in October, their hedging was about how the deals would be announced, and this view is wrong ^[16][20].